Keyphrases
Historical Prospective
100%
Acute Myeloid Leukemia
100%
Hypomethylating Agents
100%
Venetoclax
100%
Bone Marrow
33%
Leukemia
33%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
33%
Peripheral Blood
16%
Mortality Rate
16%
Increased Mortality
16%
Leukemia Patients
16%
Overcoming Resistance
16%
Length of Hospital Stay
16%
Remission
16%
Complete Remission
16%
Overall Survival
16%
Adult Patients
16%
Bcl-2 Inhibitor
16%
Both Bones
16%
Median Overall Survival
16%
Febrile Neutropenia
16%
Relapsed or Refractory Acute Myeloid Leukemia
16%
Antileukemic Activity
16%
Dismal Prognosis
16%
Tumor Lysis Syndrome
16%
Low-intensity Therapy
16%
Medicine and Dentistry
Prospective Study
100%
Acute Myeloid Leukemia
100%
Hypomethylating Agent
100%
Venetoclax
100%
Leukemia
40%
Cell Transplantation
40%
Overall Survival
40%
Hematopoietic Cell
40%
Mortality Rate
20%
Leukocyte
20%
Lactate Dehydrogenase
20%
Febrile Neutropenia
20%
Tumor Lysis Syndrome
20%
Pharmacology, Toxicology and Pharmaceutical Science
Prospective Study
100%
Acute Myeloid Leukemia
100%
Venetoclax
100%
Remission
40%
Leukemia
40%
Overall Survival
40%
Mortality Rate
20%
Lactate Dehydrogenase
20%
Febrile Neutropenia
20%
Tumor Lysis Syndrome
20%